NRAS Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P01111 |
---|---|
Clone Names | 71211140 |
Gene ID | 4893 |
---|---|
Other Names | GTPase NRas, Transforming protein N-Ras, NRAS, HRAS1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7745a was selected from the N-term region of human NRAS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | NRAS |
---|---|
Synonyms | HRAS1 |
Function | Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. |
Cellular Location | Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus membrane; Lipid-anchor Note=Shuttles between the plasma membrane and the Golgi apparatus |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NRAS is a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. This protein, which has intrinsic GTPase activity, is activated to a GTP-bound form by a GTPase activating protein and inactivated to a GDP-bound form by a guanine nucleotide-exchange factor. Defects in the gene encoding this protein are a cause of juvenile myelomonocytic leukemia (JMML).
References
Smalley,K.S., Cancer Res. 68 (14), 5743-5752 (2008)Banerji,U., Mol. Cancer Ther. 7 (4), 737-739 (2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.